ChapterPDF Available
Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us?
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International authors and editor s
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
116,000
120M
TOP 1%
154
3,900
Provisional chapter
Normal Menstrual Cycle
Barriga-Pooley Patricio and Brantes-Glavic Sergio
Additional information is available at the end of the chapter
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Barriga-PooleyPatricio and Brantes-GlavicSergio
Additional information is available at the end of the chapter
Abstract
Normal menstrual cycle represents a coordinated serial event, repeated month by month,
at regular intervals, in which the hypothalamus participates along with the secretion of
GnRH, the pituitary gland secreting follicle stimulating hormone and luteinizing hor-
mone (LH), and the ovary which responds to those hormones, recruiting a dominant
follicle and secreting estradiol and inhibin A. Estradiol stimulates endometrial prolif-
eration and production of cervix mucus. A peak of estradiol triggers discharge of LH,
responsible for ovulation and posterior secretion of progesterone by the corpus luteum,
which in turn, involutionates 14 days later if it does not receive the stimulation of hCG
(pregnancy). Normal menstrual cycles last 28 ± 7 days, being accepted a uctuation of
±2 days in the same woman, as a normal paern, what is described as a regular cycle.
Normality of these events would allow to achieve a successful embrionary implanta-
tion in the case of looking for pregnancy. For this it is required that an adequate ovule
to be fertilized is reached by a capacitated spermatozoon, during the ovulatory stage.
Spermatozoon can survive as long as 5 days at feminine genital tractum, but the ovum
is possible to be fecundated only during 12–24 hours. Fecundation occurs at the distal
third of the fallopian tube and the fecundated zygote arrives in the state of a morula, to
be implanted at the endometrium 4 days later. Once the state of blastocyst is reached, it is
detached from its shaggy area (hatching) and it is implanted in a receptive endometrium
when the window of implantation is open (days 7–9) postovulation. The rst marker of
pregnancy is the detection in maternal blood of β-hCG. No more than the 25% of fertile
couples exposed to pregnancy can achieve gestation at the month of exposure.
Keywords: menstrual cycle, fertility, concepcional cycle
1. Denition of normality
Menstrual cycle lasts 28 ± 7 days. Just a third of patients have cycles every 28 days and 82%
uctuations among 22 and 32 days [1].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
A cycle is known as regular when the frequency has a variation of no more than 2 days. The
lasting of each cycle is calculated since the rst day of menstruation until the previous day of
next menstruation. The cycle frequency is regulated by the hypothalamus-pituitary-gonadal
axis; hormones such as follicle stimulating hormone (FSH) and luteinizing hormone (LH)
must reach their eectors at the ovarian level where a dominant follicle must be recruited and
developed, secrete estradiol, in enough amounts to obtain endometrial receptivity but also
participating directly in a feedback-regulated control of the cycle.
Cycles show more irregularity in the extremes of the reproductive lifespan, during the rst
2 years from the menarche and during the perimenopausal transition. The ovarian cycle has
two stages separated by ovulation, the rst, from the beginning of the cycle to ovulation,
is called the follicular or proliferative phase. The second, between ovulation and the next
menstruation, is called the luteal phase or secretory phase.
The follicular phase is characterized by the maturation of the follicle containing an ovule and
a retinue of follicular cells, which are responsible for transforming androstenedione into estra-
diol, which in turn is released and, among many other actions, stimulates endometrial renewal.
The luteal phase, named because the follicular cavity that left the ovule after hatching, is
transformed into a corpus luteum and continues to produce estrogen, but it also releases
important amounts of progesterone. The luteal phase is preceded by a signicant increase in
LH, and ovulation marks its onset; then, it lasts ±14 fairly constant days when comparing dif-
ferent women. During this phase, the average total body temperature of women is constantly
0.5°C higher than in the follicular phase.
If there is no embryo implantation, the endometrium is detached giving rise to menstrual
ow, which has normal volume parameters, up to 80 mL, in duration, 3–8 days, content,
absence of clots and symptoms, and absence of pain.
It is considered that the conserved cyclicity expresses that the hypothalamic-pituitary-gonadal
axis is healthy. The ovaries do not alternate to ovulate.
2. Important concepts
Ovarian reserve: it corresponds to the number of follicles that a woman has and it is dened during
fetal life and then the number of follicles goes slowing down gradually.
When is born, each woman counts with a xed number of ova, which are geing lost with the
past of years (atresia) Delaying maternity is nonrecommendable, since at higher age the risk
of not having ovum of a good quality at the moment when a pregnancy is planned.
In a woman fertility, among 38–40 years is lower than at 25–30 years. Atresia of oocytes is a
continuous process that never stops not even with the use of anovulatory or pregnancy.
Oocyte atresia: it is the mechanism of follicular apoptosis that seems to contribute to the selection of
optimal ovules. During the early fetal stage, about 7,000,000 oocytes are formed in the ovary.
Menstrual Cycle2
Before birth, the ovular reserve has been reduced to one-third by mechanisms of apoptosis
(programmed death).
At birth, only 1–2 million oocytes remain in the ovary and during puberty, there are usually
300,000 available for eventual ovulation. In fact, they will only ovulate between 400 and 500
throughout the lifespan. Then, through the female reproductive life, between the periods of
puberty and menopause, about 250,000 follicles will be destined to die, reaching less than
1000 during perimenopause (Figure 1).
Sex steroids—estrogens and progesterone: Estrogens are steroid hormones produced by the
granulosa follicle, the corpus luteum, and the placenta (if there is pregnancy). Its synthesis
comes from cholesterol molecules. Progesterone is synthetized by corpus luteum and pla-
centa, if there is pregnancy.
Of the estrogens, the most potent is estradiol. The actions they develop are:
Female genital apparatus: they stimulate the growth and development of the female sexual
organs and the proliferation of the endometrium during the sexual cycle.
Breast: they favor the growth of the mammary ducts and are, in part, responsible for the
development of the mammary gland during puberty.
Bone: they regulate the osteoclastic activity and stimulate the osteoblastic activity, in such a
way that they are essential to maintain adequate bone mineralization.
Figure 1. The number of oocytes in any woman comes dened at the moment of birth and slow down inevitably during
her life during her life from 1 to 2 million at the moment of birth at 300,000 to go decreasing through her life 25,000 at
37–38 years and near 500 during the postmenopause.
Normal Menstrual Cycle 3
Cardiometabolic: estrogen relaxes the smooth muscle of arterioles, increases HDL choles-
terol, and lowers LDL cholesterol, which has been associated with the lower incidence of
cardiovascular disease that women have in relation to men, especially before menopause.
Progesterone is also a steroid hormone. It is responsible for the progestational changes of the
endometrium. On the breasts, progesterone stimulates the development of the lobes, being its
action complementary to that of the estrogens. Progesterone is thermogenic and contributes
to the increase in basal temperature experienced by some women after ovulation.
3. Follicular phase
Follicular phase begins the very rst day of menstruation. The development of ovarian fol-
licles, named folliculogenesis, begins at the last days of menstrual cycle before the release of
mature follicle during ovulation (Figure 2).
When a pregnancy did not occur, the release of inhibin A and sex steroids are reduced by the end
of the functional period of the corpus luteum. Both falls contribute to reduce the release of FSH
by feedback at the central level, which is dependent on pulsatility of hypothalamic GnRH. This
is how FSH increases during the last days of the menstrual cycle (Figures 3 and 4) [2].
Figure 2. The menstrual cycle has two phases, follicular phase and luteal phase. The follicular phase begins with
menstruation. The follicle stimulating hormone (FSH) increases released by the anterior pituitary gland and stimulates
follicular growth and estradiol production. The 17 beta-estradiol produced by the follicles exerts negative feedback on
the FSH. Estradiol continues to increase due to the growth of the dominant follicle. The LH increases sharply to trigger
ovulation. Immediately after ovulation, the luteal phase begins. The corpus luteum produces progesterone and 17 beta-
estradiol concentrations of progesterone and estradiol decrease, menstruation begins a new cycle, unless a pregnancy
has been established.
Menstrual Cycle4
The progressive elevation of FSH allows many follicles to be recruited simultaneously.
Nevertheless, only some persist, in such a way that an approximate 99% of the cycles, only a
dominant follicle will be destined to ovulate, during the next menstrual cycle.
The remaining 1% has codominance, that is two dominant follicles, which eventually can
generate a double ovulation at the risk of a multiple pregnancy.
In women from 19 to 42 years, follicular phase has an average duration of 14.6 days, however,
to be precise on each woman in what step of the cycle she is very dicult because of the fol-
lowing reasons:
Duration of menstrual cycle is very changing, even among young women of similar ages,
with variations described from 25 to 34 days.
Figure 3. Dynamic scheme of follicular activity and the changes in gonadotropins, steroids, and inhibins during follicular
phase of menstrual cycle.
Figure 4. The level of inhibin changes through menstrual cycle. Inhibin B dominates follicular phase during the cycle
while inhibin A dominates luteal phase.
Normal Menstrual Cycle 5
Menstrual Cycle6
During the follicular phase, FSH is responsible for recruitment among those follicles that
remain available. Between days 5 and 7 of the cycle, follicular selection normally occurs, to
allow only one follicle, the dominant follicle (FD) to ovulate and the rest to experience atresia.
Anti-müllerian hormone (AMH), which is secreted in the granular layer, also participates in
the selection of FD. On day 8 of the cycle, the FD promotes its own growth, suppressing the
maturation of the other ovarian follicles.
During the follicular phase, estradiol plasma levels are higher along with the growth of the
number of granulosa cells and the growth of the DF. FSH receptors are found exclusively in
the cell membrane of granulosa cells. The increase in FSH during the late luteal phase induces
its own FSH receptors and eventually increases the secretion of estradiol by the granulosa
cells by transforming androstenedione, which diuses from the theca cells (Figure 7).
It is important to point out that the increase in the numbers of receptors of FSH is due to an
increase in the population of granulosa cells and not to an increase of the concentration of recep-
tors of FSH on them. Each granulosa cell has 1500 receptors of FSH at secondary stage of follicular
development, and the number of receptors of FSH stays constant during the rest of DF growing.
The increase in estradiol secretion also upregulates their own receptors, increasing the total of
estradiol receptors (ER) in the granulosa cells. On the other hand, in the presence of estradiol,
FSH stimulates the formation of LH receptors in the same cells, which allows the secretion of
small amounts of progesterone and 17-hydroxyprogesterone (17 OHP) that would exert posi-
tive feedback on the pituitary gland. Already sensitized by the increase of estrogen, thus allow-
ing the release of luteinizing hormone (LH) and achieve its peak. FSH also stimulates many
steroidogenic enzymes such as aromatase and 3β-hydroxysteroid dehydrogenase (3β-HSD).
Figure 6. Time lapse of recruiting, selection, and ovulation of dominant follicle (DF) with the beginning of atresia in the
other follicles of the group. Adapted from Hodgen [4].
Normal Menstrual Cycle 7
There are other signaling pathways that impact the dierentiation of theca cells, not only LH
but also insulin-like 3 (INSL3) that appear to modulate LH-mediated androgen biosynthe-
sis and increased follicle cell apoptosis and luteal regression, bone morphogenetic proteins
(BMPs) produced by granulosa cells, and/or oocytes who antagonized the eects of LH and
INSL3, the circadian clock genes, androgens, and estrogens and (2) theca-associated vascular,
immune and broblast cells, as well as the cytokines and matrix factors that play key roles in
follicle growth [6].
At Table 1, production rates are presented for sexual steroids during follicular phase, luteal
phase at the moment of ovulation.
Dierently from granulose cells, LH receptors are localized at theca cells during all of the
stages of menstrual cycle. LH receptors stimulates granuloma’s cells. LH stimulates the pro-
duction of androstenedione and at a lesser level the production of testosterone at the theca
cells.
Androstenedione is then transported to the cells of granulosa where it is aromatized, and
nally, it becomes estradiol 17-β-hydroxysteroid dehydrogenase type I. This is known as the
Sex steroids*Early follicular Preovulatory Mid-luteal
Progesterone (mg) 1 4 25
17α-Hydroxyprogesterone (mg) 0.5 4 4
17α-Hydroxyprogesterone (mg) 7 7 7
Androstenedione (mg) 2.6 4.7 3.4
Testosterone (μg) 144 171 126
Estrone (μg) 50 350 250
Estradiol (μg) 36 380 250
*Values are expressed in milligrams or micrograms per 24 hours.
From Baird and Fraser [7].
Table 1. Production rate of sex steroids in women at dierent stages of the menstrual cycle.
Figure 7. Diameter of dominant follicle (DF) days prior to LH peak and plasma concentration of estradiol per follicle
diameter (curved lines are 95th and 5th percentiles). Adapted from Macklon and Fauser [5].
Menstrual Cycle8
hypothesis of two cells and two gonadotropins of the regulation of synthesis on the ovary
(Figure 8).
The normal follicular phase has been divided in two stages: (a) early and (b) middle and (c)
late, to allow a beer comprehension of the endocrine events that will be nally responsible
of ovulation.
Early follicular phase (days 1–4): it begins with the rst day of menstruation. Follicular
recruitment occurs due to the elevation of FSH, as a consequence of the decrease in estradiol,
progesterone, and inhibin A released by the corpus luteum of the previous cycle, allowing
the number of LH receptors to increase in the cells of the teak and the granulosa. The plasma
levels of estradiol tend to remain low at this stage (Figure 1).
Medium follicular phase (days 5–7): as the recruitment and growth of follicles induced by
FSH progress, estradiol increases slowly in a progressive manner thanks to the increased
activity of CYP19, an FSH-dependent aromatase that is present in granulosa cells. The
follicle that achieves the highest number of FSH receptors may aromatize more estradiol
and become the dominant follicle. The other follicles, with fewer receptors for FSH, suer
atresia. For estrogen synthesis, it is necessary for the thecal cells to produce androgens,
under the stimulus of LH, and for these to diuse to the granulosa cells. Simultaneously,
two glycoproteins, activin and inhibin, are produced in the theca and granulose, with local
actions. Inhibin B exerts a negative hypophyseal feedback eect, where it potentiates the
eect of estradiol and inhibits the synthesis and release of FSH [9, 10]. This would be
a mechanism to achieve dominance giving an advantage to the follicle that has greater
Figure 8. Two cells and two gonadotropins, on the regulation and the synthesis of estrogens at the ovary. From: Doshi
and Agarwal [8].
Normal Menstrual Cycle 9
development. The estrogen take-o (ETO) marks the successful establishment of the domi-
nance of a follicle.
The FD develops its internal theca and increases receptivity to LH, which stimulates the pro-
duction of androgens by degrading molecules of cholesterol to progesterone and from this to
dehydroepiandrosterone, androstenedione, and testosterone.
At the end of this phase, the granulosa-theca complex of the FD has almost complete function-
ality to enter the late follicular phase.
Late follicular phase (days 8–12): this period is characterized by the elevation of estrogens
that come from the DF, reaching its maximum values between 40 and 50 hours, before an
elevation of FSH that precedes the ovulatory peak of LH. This preovulatory follicle reaches an
average diameter of 15–20 mm.
3.1. Follicular phase and fertility
The moment of greatest likelihood of successful fertilization is intercourse on the day before
ovulation. However, the potentially fertile period, which depends on sperm survival, can
extend from 5 days before ovulation. Those pregnancies that have been obtained after day 14,
are associated with later ovulation, a normal variability in the duration of the follicular phase
depending on the time of the ETO.
It is believed that cycles of 30–31 days and 5 days of bleeding would have a higher probability
of pregnancy [11], perhaps due to beer quality of the DF, good function of the corpus luteum
and optimal endometrial receptivity. The moment of the fertile window is quite variable. It
has been reported that a signicant number of women with regular menstrual cycles can be
in their fertile window before day 10 or after day 17, of their menstrual cycle [12]. However, it
seems that the possibility of pregnancy is low when the cycles are short, less than 25 days [13].
In clinical practice, to determine the fertility potential of a given cycle, indirect methods
are used, which require observing at least one of the three primary signs of fertility (basal
body temperature, cervical mucus and position of the cervix), known as methods based on
symptoms.
There are kits to detect the increase in LH, which occurs 24–36 hours before ovulation named
ovulation predictor kits (OPK). Those urine-based ovulation test kits are available in versions
standard OPKs, digital OPKs or advanced digital OPKs, but some saliva-based ovulation tests
are available also.
Computerized devices that interpret basal body temperature, urinary test results, or changes
in saliva are called fertility monitors, and there are dierent types: urine-based fertility moni-
tors, perspiration-based fertility monitors and saliva-based fertility monitors.
In the monitoring of assisted fertility procedures, eective follicular follow-up with ultraso-
nography is preferred.
In infertility treatments, ovulation inducers are used that increase endogenous levels of
FSH or eleven therapeutically by administering FSH parenterally, which manages to rescue
Menstrual Cycle10
multiple follicles from atresia. So, this patient has a higher risk of multiple ovulation. It is
interesting to note that when rescuing follicles from atresia, the follicular endowment remains
the same, so that follicles will not be depleted in an accelerated manner.
3.2. Follicle types
At born, woman count with primordial follicles (PF), each surrounded by one layer of cells of
granulosa and are detained at the pro phase of the rst meiotic division.
During adolescence, the woman has antral follicles that depend on FSH. On average, this fol-
licle takes 14 days to mature to preovulatory FD. They are derived from a recruitment process
that is independent of FSH and is mainly regulated by the anti-müllerian hormone (AMH),
which is produced by the granulosa cells of the follicles in early development and inhibits
the transition from the primordial to the primary follicular stage [14]. AMH levels can be
measured in serum and used to measure the follicular reserve (Figures 9 and 10).
Primordial follicles (PF) are independent of FSH. Their average life is 60–65 days, then they
are transformed in to preantral follicles (PAF), also independent of FSH, and are surrounded
by many layers of granulosa’s cells and also by theca cells. In this process, many primordial
follicles suer atresia (Figure 11).
Due to the presence of 5α-reductase, the early preantral and antral follicles produce more
androstenedione and testosterone compared to the estrogen rate. 5α-reductase is the enzyme
responsible for converting testosterone to dihydrotestosterone (DHT). Once testosterone has
been reduced by 5α, DHT cannot be aromatized.
Figure 9. AMH is involved in the paracrine control of recruitment in the rst stage, when the process is still independent
of gonadotropins. AMH can not only reect the number of early antral follicles in the process of development, but also
those in earlier stages. Adapted from Ref. [1].
Normal Menstrual Cycle 11
With the increase in age in women, the involution of granulosa cells decreases the levels of
inhibin production. Because of this, when a woman approaches menopause her FSH levels
become higher, a sign that her ovarian reserve has decreased. On the other hand, the peri-
menopausal follicles are of the worst quality, half have chromosomal alterations.
As mentioned, the development of the preantral follicle is independent of FSH, so any follicle
that grows beyond this point will require an interaction.
Figure 11. Follicular dynamics and illustration of folliculogenesis process.
Figure 10. Clinical witnesses of the follicular development in stage pre- and postdependence of FSH: AMH and
ultrasound, respectively. Adapted from Ref. [15].
Menstrual Cycle12
Secretion of gonadotropin is regulated by the releasing hormone of gonadotropin (GnRH),
steroidal hormones, and diverse peptides released by dominant follicle.
Among substances that can be found al follicular liquid there are steroids, pituitary hormones,
plasmatic proteins, proteoglycans, and ovarian factors nonsteroidal, which regulate the micro
environment of the ovary and the steroidogenesis of the granulosa.
Factors of growing such as the insulin growth factors 1 and 2 (IGF1, IGF2) and the epider-
mal growth factor (EGF) would have an important role at the development and maturity of
oocytes. Concentration of ovarian steroids is higher at follicular liquid compared to plasmatic
concentrations.
There are two population of antral follicles: big follicles, which measure more than 6 mm
diameter, and lile follicles, less than 8 mm. In big follicles, concentrations of FSH are
higher. Estrogen and progesterone are higher as well, while prolactin concentration is
lower. Inside lile follicles, prolactin and androgen levels are higher in comparison to big
antral follicles.
In addition, as mentioned, FSH increases during the early follicular phase and then begins to
decrease until the ovulation phase, except in the short preovulatory peak. In contrast, LH is
low in the early follicular phase and begins to increase in the middle follicular phase due to
positive feedback of increasing levels of estrogen.
To achieve positive feedback of LH release, plasma estradiol should be greater than 200
pg/ml, for at least 48 hours. The gonadotropins are secreted in a pulsatile manner in the ante-
rior pituitary, with a frequency and widening of pulses that change according to the phase of
the menstrual cycle (Figure 12).
Figure 12. Pulses of LH throughout a normal cycle. Number of pulses per 24 h decreases, but total daily secretion and
LH half-life are stable. The intersecretory burst interval becomes longer as the cycle progresses, being very long in the
luteal phase, whereas the pulse amplitude of LH shows a dichotomous behavior, with small and high waves. Adapted
from data of Sollenberger et al. [16].
Normal Menstrual Cycle 13
During early follicular phase, secretion of LH occurs to a frequency of pulse from 60 to 90 minutes
with a widening of pulse constant but variations on number of pulses intersecretory burst
interval and pulse amplitude [16]. During late follicular phase, previous to ovulation, fre-
quency of pulse increases and widening may be beginning to increase. Most of women have
widening of pulse of LH beginning to increase after ovulation.
Once menstruation is produced, levels of FSH begin to decrease due to negative retro alimen-
tation on inhibin B produced by developing follicle.
4. Ovulation
Hatching occurs 10–12 hours after peak of LH (Figure 8). Augmentation of LH is generated
by signicative raising of estradiol, with levels between 200 and 450 pg/mL, produced at the
preovulatory follicle.
The critical concentration of estradiol needed to initiate positive feedback requires that the
dominant follicle reach a size >15 mm in diameter. The increase in LH occurs 34–36 hours
before ovulation and is a very reliable predictor of ovulation (Figure 9). This increase in LH is
responsible for the luteinization of granulosa cells that stimulates the synthesis of progester-
one and also estradiol. In addition, the LH increase resumes the second meiotic division and
the chromosomal reduction in the oocyte with the release of the rst polar corpuscle.
Estradiol levels decrease abruptly immediately before peak of LH. This can be due to regula-
tion to down of LH from its own receptor or due to direct inhibition of estradiol synthesis
because of progesterone.
Progesterone also participates in the stimulation of the increase in FSH in the middle of the
cycle (Figure 13).
This increase in FSH would produce the release of oocytes from their follicular junctions, to
stimulate the plasminogen activator and increase the LH receptors in the granulosa. The exact
mechanism responsible for the post ovulatory fall is unknown.
Decrease in LH would occur as the consequence of the loss of positive retro alimentation of
estrogens the inhibitory retro alimentation of progesterone (Figure 14).
It takes 36 hours from the peak of estrogen until ovulation occurs. The time to ovulation mea-
sured from the peak of LH is 12 hours; considering the time of detection in urine, ovulation
will take place at 24 hours since LH is measured in the urine. The hormone hCG is similar to
LH and can be used as an exogenous hormone to trigger ovulation, which will occur 36 hours
after administration.
During the ovulatory period, progesterone and prostaglandins are secreted inside the follicle,
as well as proteolytic enzymes. This results in digestion and rupture of the follicular wall
allowing hatching, commonly called ovulation [18].
Menstrual Cycle14
Figure 13. Increase of LH precedes ovulation in 36 hours. Peak, on the other side, precedes ovulation in 10–12 hours.
Figure 14. Changes in ovarian gonadotropins and steroids in the middle of the cycle, just before ovulation. The beginning
of the increase of LH is at time. 0 time. Abs: E2, estrogen; P, progesterone. Adapted from Ho et al. [17].
Normal Menstrual Cycle 15
Proteolytic enzymes and prostaglandins are activated in response to LH and progesterone
and digest collagen in the follicular wall, which leads to an explosive release of the cumulus-
oocyte complex. Prostaglandins can also stimulate the release of oocytes, stimulating the
smooth muscle within the ovary.
The point of the dominant follicle closest to the ovarian surface where the rupture occurs is
called a “stigma.”
All the mechanisms are still not elucidated. The concentrations of prostaglandins E and F and
hydroxyeicosatetraenoic acid (HETE) reach a maximum level at the follicular level just before
ovulation.
Prostaglandins stimulate proteolytic enzymes, whereas HETE stimulates angiogenesis and
hyperemia. The use of high doses of prostaglandin inhibitors could hinder the follicular rup-
ture, causing what is known as luteinized unruptured follicle syndrome, and can be observed
in fertile and infertile women.
Consequently, it should be recommended to women in search of pregnancy and especially
that with fertility problems, avoid the intake of inhibitors of prostaglandin synthesis, and
inhibitors of cyclooxygenase (COX), in fact, are being investigated as an alternative to morn-
ing after pill in emergency contraception [19, 20].
For ovulation to occur, a series of complex molecular mechanisms that commence after the
gonadotrophin surge must be given. These include intracellular signaling, gene regulation,
and remodeling of tissue structure in each of the distinct ovarian compartments, which can be
summarized in (a) ovulatory mediators that exert eects through the cumulus cell complex,
(b) convergence of ovulatory signals through the cumulus complex co-ordinates the mechanistic
processes that control oocyte maturation and ovulation, and (c) other multiple inputs, including
Figure 15. Proposed mechanisms at follicular rupture. LH stimulates the expression of genes in granulosa cells
(PR, PGS-2) that control the activation of matrix metalloproteinases (MMPs), leading to the breakdown and remodeling of
extracellular matrices and the surface epithelium to allow rupture of the follicle and extrusion of the oocyte (ovulation).
Modied from Richards et al. [22].
Menstrual Cycle16
endocrine hormones, immune and metabolic signals, as well as intrafollicular paracrine factors
from the theca, mural and cumulus granulosa cells, and the oocyte itself. Therefore, healthy
and meiotically competent oocytes and the coordination and synchronization of endocrine,
paracrine, immune, and metabolic signals acting mainly through the cumulus compartment
exert control on oocyte maturation, developmental, and ovulation process [21].
Mechanisms suggested implied in follicle rupture [22] are shown in Figure 15.
5. Luteal phase
This phase lasts 14 days in most women after ovulation. The granulosa cells that are not
released with the oocyte acquire a vacuolated appearance and a characteristic yellow color
due to the concentration of a carotenoid called lutein and the incorporation of fat drops. No
other function has been described for lutein than being a powerful antioxidant.
The luteinized cells combine with the newly formed theca-lutein cells together with the sur-
rounding stroma; thus, originates the transitory endocrine organ that secretes progesterone,
known as the corpus luteum, whose main function is to prepare the endometrium, already
proliferated by the action of follicular phase estrogens, for the implantation of the fertilized egg.
The endometrium expresses adhesion molecules that make it receptive to the blastocyst and
between days 7 and 9 from ovulation, a period of maximum eciency known as the window
of implantation is established; after day 9, implantation is not possible, which is why it is
called the refractory phase.
Eight or nine days after ovulation, at the time when implantation is expected, maximum vas-
cularization is reached, the basal lamina dissolves, and the capillaries invade the granulosa
cell layers in response to the secretion of angiogenic factors, both from the granulosa and from
the theca cells, in harmony with the maximum levels of plasma progesterone and estradiol.
The survival of the corpus luteum depends on the continuous stimulation of LH, but estradiol
metabolites, acting via paracrine-autocrine pathways, aect angiogenesis or LH-mediated
events also [23].
The function of the corpus luteum decreases at the end of the luteal phase unless chorionic
gonadotropin appears due to an eventual pregnancy. If pregnancy does not occur, the corpus
luteum undergoes luteolysis. Under the action of estradiol and prostaglandins, it forms a scar
tissue called corpus albicans [24].
As noted, estrogen levels increase and decrease twice during the menstrual cycle, increase dur-
ing the middle follicular phase, and then decrease rapidly after ovulation, followed by a further
increase during the middle luteal phase, in parallel with the increase in serum levels of proges-
terone and 17α-hydroxyprogesterone, all falling at the end of the menstrual cycle (Figure 1).
The mechanism of how the corpus luteum regulates steroid secretion is not known exactly. It
may be determined in part by the paern of LH secretion, changes in its receptor, or variations
Normal Menstrual Cycle 17
in the levels of enzymes that regulate the production of steroid hormones. The amount of
granulosa cells formed during the follicular phase and the levels of LDL cholesterol that sur-
round it may also play a role in the regulation of steroid synthesis by the corpus luteum.
There are at least two types of luteal cells, large and small.
Both produce progesterone but with dierences. Large cells come from granulosa, are more active
in steroidogenesis, produce large amounts of progesterone, and although they have numerous
LH receptors, they do not elevate progesterone secretion in response to LH or cAMP. Instead,
they possess receptors for PGF2a and respond to this hormone with activation of at least two
second messengers. Activation of protein kinase C (PKC) decreases progesterone’s secretion.
As a result of the binding of PGF2a to its receptor, the concentration of free intracellular
calcium increases, which seems to be related to the induction of apoptosis and cell death.
The large cells are inuenced by other autocrine and paracrine factors, such as inhibin, relaxin,
and oxytocin (Figure 16). The small cells are derived from the theca, contain receptors for LH,
and respond to LH or cAMP by increasing the secretion of progesterone by 5–15 times [25, 26].
The synthesis of progesterone by the corpus luteum is essential for the establishment and
maintenance of pregnancy.
Figure 16. Regulation of small luteal cells (left) and large (right). In small luteal cells, the binding of LH to its receptor
activates the second messenger protein kinase A (PKA) pathway, which stimulates the synthesis of progesterone. In
large cells, the LH that binds to its receptor does not increase the intracellular concentrations of cAMP nor the synthesis
of progesterone, but the binding of PGF2a to its receptor activates PKC, which inhibits the synthesis of progesterone
and causes an inux of calcium that leads to cell degeneration. AC: adenylate cyclase, DAG: diacylglycerol, IP3: inositol
1,4,5-trisphosphate, PIP2: phosphatidylinositol 4,5-bisphosphate, and PLC: phospholipase C. From Niswender [25].
Menstrual Cycle18
In addition to luteinization, that is, the conversion of an ovulatory follicle into the corpus
luteum and luteal regression to allow a new cycle, there are also mechanisms of luteal main-
tenance and rescue to sustain pregnancy.
Humans preferably use circulating LDL cholesterol for steroidogenesis although the corpus
luteum has the ability to synthesize its own cholesterol, in smaller amounts [27].
Inside the cells, lipid steroid precursors are found as free cholesterol. There is also esteried
cholesterol that accumulates within the rough endoplasmic reticulum and as cytoplasmic
lipid droplets or lipoprotein particles. These fay acid esters of cholesterol cannot replace free
cholesterol as a structural ingredient of the plasma membrane nor serve as direct substrates
for the production of steroids. They are hydrolyzed by a neutral cholesterol ester hydrolase
(NCEH), also known as hormone-sensitive lipase, because their activity is tightly regulated in
steroidogenic tissues by FSH, LH, and hCG.
Progesterone secretion and estradiol during luteal phase is tightly connected with the pulses
of secretion of LH (Figure 12). The frequency and widening of secretion of LH during fol-
licular phase regulates the function of the posterior luteal phase and is concordant with the
function of LH during luteal phase.
The frequency and widening of the pulses of secretion of pituitary LH aect the secretion of
progesterone and estradiol during the luteal phase (Figure 12).
The half-life of the corpus luteum can be reduced with the continuous administration of LH
during any of the phases, follicular or luteal, as if the LH concentration is lower or its pulses
are reduced.
The luteal phase can suer shortening also if the levels of FSH are inadequate or low, during
the follicular phase, conditioning the development of a smaller corpus luteum.
The function of the corpus luteum begins to decrease 9–11 days after ovulation. The mecha-
nism by which the corpus luteum undergoes involution (luteolysis) is partially elucidated.
Prostaglandin F2α would have a luteolytic action, through the synthesis of endothelin-1 that
inhibits steroidogenesis and stimulates the release of a growth factor, the tumor necrosis fac-
tor alpha (TNFα) oxytocin, and vasopressin and would produce a luteotropic eect through
an autocrine/paracrine mechanism.
The ability of LH to negatively regulate its own receptor may also play a role at the end of
the luteal phase; thereby, the involution of the corpus luteum must be caused by a decrease
in the sensitivity of the LH receptors, rather than by a pulsatile secretion of it. Finally, the
matrix metalloproteinases would also play a role in luteolysis and, therefore, in the fall of
progesterone levels.
6. Menstruation
In the absence of pregnancy, the levels of progesterone and estradiol begin to decrease as a
result of the corpus luteum decreasing. The fall of progesterone increases in degree of coiling
Normal Menstrual Cycle 19
and the constriction of the spiraled arterioles. This nally produces tissue ischemia due to
decreased blood ow from the supercial, spongy, and compact endometrial layers. After the
fall of serum concentrations of ovarian steroids, matrix metalloproteinases play a key role in
the onset of menstrual bleeding in the human endometrium, by inducing the degradation of the
extracellular matrix of this mucosa [28]. Endometrial prostaglandins cause contractions of the
uterine smooth muscle and detachment of degraded tissue.
The release of prostaglandins may appear due to instability of the lysosomal membranes in
the endometrial cells. The magnitude of this eect is such that inhibitors of prostaglandin
synthesis can be used as a therapy in women with excessive uterine bleeding. Menstrual ow
is composed of detachment of endometrial tissue, red blood cells, inammatory exudates,
and proteolytic enzymes.
Two days after the start of menstruation and while the shedding of the endometrium still
occurs, the estrogen produced by the new growing follicles begins to stimulate the regen-
eration of the supercial layers of the endometrium. The estrogen secreted by the growing
follicles causes a long constriction of the vessel facilitating the formation of a veil over the
denuded endometrial vessels.
The average duration of menstruation is 4–6 days, but the normal range can be 2–8 days.
As mentioned above, the average amount of bleeding loss is 30 ml and more than 80 ml is
considered abnormal. A few years ago, a classication has been generalized to describe the
abnormalities of bleeding suggested by the International Federation of Gynecology and
Obstetrics [29].
6.1. Types of endometrium at echographies
The characteristics of the endometrium in gynecological ultrasound change depending on the
period of the menstrual cycle, presenting dierent thicknesses according to the stage of the
menstrual cycle (Figure 17).
Endometrium type 0, postmenstrual: it is characterized because only a ne refractive line
can be seen. It is the endometrium typical of postmenopause, postpartum, or after a uterine
scraping. Most postmenopausal women are between 3 and 5 mm thick, but it is normal up to
8 mm if there has been no unexpected bleeding.
Endometrium type 1, preovulatory: trilaminar endometrium, refers to the observation of
three refractive lines. This stage corresponds to the proliferative or estrogenic phase. In an
early follicular stage, the size of the endometrium is between 3 and 4 mm thick, while in the
stage close to ovulation, it can reach 9–11 mm.
Endometrium type 2, postovulatory: in this stage, the progesterone matures the already
proliferated endometrium, especially in its glandular and vascular structures, thickening the
endometrium. The ultrasound image becomes whiter to the extent that it contains more water
and glycogen. This layer of refringency represents most of the endometrium toward the end
of the luteal phase.
Menstrual Cycle20
Endometrium type 3, premenstrual: in this stage, there is only one large refractive line and
corresponds to the late secretory phase.
6.2. Endocrine regulation of the menstrual cycle
When the gonadal axis has reached maturity, the neurons of the preoptic area and the infun-
dibular and arcuate nuclei in the hypothalamus secrete GnRh in a pulsatile fashion, every
60–90 minutes, to the pituitary portal system.
Frequency and amplitude are essential to produce and maintain the eect on the gonado-
tropic cells of the anterior part of the pituitary gland, which consists of releasing both LH and
FSH. The secreted amounts of each will depend not only on the pulsatility of GnRH, but also
on the positive and negative feedbacks mechanisms of sex steroids.
In general, estrogen sensitizes and counter-regulates FSH, at both levels, the hypothalamus
and the adenohypophysis, selectively modulated by other factors such as inhibins A and
B. LH is sensitive to positive feedback, while there are estrogens in the late follicular phase
and in the luteal phase, but the feedback becomes negative when estrogen levels fall at the
end of the cycle.
Figure 17. The main substrate for human steroidogenesis is LDL cholesterol: it is incorporated by endocytosis and
stored as free cholesterol or as ester. Esteried cholesterol is hydrolyzed cholesterol esterases (CE) and transported as
free cholesterol to the mitochondria. It passes from the outer mitochondrial membrane to the internal membrane, with
the concurrence of the steroidogenic acute regulatory protein (StAR), peripheral type benzodiazepine receptors and
endozepine. In mitochondria, cholesterol is converted to pregnenolone by cytochrome P450scc, which is transported out
of the mitochondria and converted to progesterone by 3b-hydroxysteroid dehydrogenase, D5, D4 isomerase (3b-HSD),
which is present in the smooth endoplasmic reticulum (The cell nucleus is not shown.)
Normal Menstrual Cycle 21
Recent evidence indicates that the administration of progesterone in the late well-estrogenized
follicular phase does not prevent the LH surge, which is of great importance because it would
have no interference with ovulation [30, 31].
Relatively, low levels of estradiol, in early follicular and luteal phases, decrease kisspeptin
expression, which reduces the amplitude of GnRH pulses [32]. On the other hand, progester-
one would increase the dynorphin expression, which in turn reduces that of kisspeptin. These
changes have been associated with the lower frequency of GnRH pulses in the luteal phase.
Other modulators that stimulate the pulsatile secretion of GnRH are glutamate and norepi-
nephrine, while GABA and endogenous opioids inhibit it.
Neurokinin B and dynorphin neuropeptides act in an auto-synaptic fashion in the arcuate/
infundibular nucleus, so that an increase in the expression of neurokinin B (NKB) stimulates
the secretion of and, therefore, of GnRH, while an increase in dynorphin (Dyn) expression
decreases kisspeptin secretion by inhibiting the pulsatility of GnRH. This system is known
as KNDy [33].
At the beginning of the menstrual cycle, estradiol levels are low and FSH levels are slightly
elevated. This ratio manages to recruit follicles and as that happens, not only estradiol
increases but also inhibin A, due to the empowerment of FD, which generates a continuous
decrease in FSH in the follicular phase.
The concentrations of FSH reach the maximum levels on the day when the FD is dened, fol-
lowed by a slow decrease during the follicular phase, from day 5 to 13, reaching a nadir and
then a peak just before ovulation (Figure 14). There comes a time when estradiol levels are
such that they trigger the peak of FSH and LH, producing ovulation.
Figure 18. Types of endometrium in transvaginal ultrasound. The endometrium was classied into four types (0, 1, 2, and 3)
according to the appearance of the myometrium-endometrium and endometrium-endometrium interfaces, the texture,
and the thickness of the functional layer. Type 0: smooth, thin as a pencil line; type 1: trilaminar structure with an iso- or
hypoechoic functional layer; type 2: also trilaminar, but the myometrium-endometrium interfaces are thicker than those
of type 1; and type 3: thick and homogeneous echogenic image. The type of endometrium correlates with the day of the
menstrual cycle. Ultrasound is dened on day 0 as the day of the follicle break. Type 0 is usually found on day 11, during
and immediately after menstruation. Type 1 is observed during the middle follicular phase and until day +2. Types 2
and 3 are observed after the ovulatory days. The endometrium increases more thickness during the preovulatory phase
(average +5.5 mm), and in the luteal phase, the average is +2.6 mm.
Menstrual Cycle22
As the luteal phase advance in time, inhibin A, estradiol, and progesterone fall together with
the increase in activin A. FSH increases in the transition from the luteal phase to the next
follicular phase, beginning 4 days before menstruation, a stage in which inhibin B increases
during follicular recruitment.
The concentration of activin A secreted by the follicles increases in the second half of the luteal
phase [34] (Figure 18), decreases at the beginning of the follicular phase, increases during the
early follicular phase, and then increases during the middle follicular phase in parallel with
estradiol and inhibin A (Figure 19).
In older women, FSH is higher, even during nadir, and the increase occurs early during the
luteal phase. Recruitment of a group of follicles begins early, but the selection of DF is altered
and can either advance or delay. The result is the variability of the cycle at the expense of a
variable follicular phase, called “lag phase,” which ends when the ETO is produced [35].
The ETO is when the estradiol overt elevation is achieved, which marks the selection of the
FD. If an FD capable of ovulating was not achieved, the woman can go through a hyperes-
trogenic state without establishing a corpus luteum, so at the endometrial level, the cycle
is hormonally monophasic. This is the pathophysiological basis that explains the mono-
phasic hyperestrogenism that aects approximately one-third of women in perimenopause
(Figure 20).
Figure 19. Scheme composed shows luteal events, follicular ones and hormonals during luteal phase of woman
CL = corpus luteum; DF = dominant follicle; WEM1–3 = wave emergency 1, 2, or 3 at the cycle; the waves of follicle of
light gray color indicates the low frequency of the principal waves (selection of DF) during luteal phase or early follicular
ones in women of 2 or 3 waves. The estradiol rise in the follicular phase begins after the emergence of the ovulatory DF
and becomes more rapid following DF selection, and occurs earlier in women with 2 versus 3 follicle waves per cycle.
After ovulation, estradiol concentrations increase to the mid-luteal phase (days 7–9 after ovulation) and then decline,
and this is due to luteal estradiol secretion and is unaected by minor or major anovulatory waves. Adapted from
Macklon and Fauser [5].
Normal Menstrual Cycle 23
A chronic negative energy imbalance reduces the pulsatility of LH, generates atresia of FD
and, consequently, anovulation and amenorrhea. Weight loss is associated with a reduc-
tion in LH pulses, which generates functional, reversible hypothalamic amenorrhea. On the
contrary, the pulsatility of LH is increased in adolescents with irregular cycles or in women
with polycystic ovary syndrome, associated with anovulation also, but here the selection of
DF is absent.
7. Conclusion
Human reproduction depends on the integrity of a system of intracrine and paracrine signals
within the ovaries, in which those recruited follicles that have reached a level of dierentia-
tion that make them sensitive to the endocrine control of the other distant and great actor,
the hypothalamus axis participate pituitary. Once a dominant follicle has been achieved, the
elevations of the circulating levels of estradiol and inhibin B produced by it will modulate FSH
levels and will allow, on the one hand, the atresia of the other follicles, and on the other, they
will facilitate the LH surge, necessary to trigger ovulation. After hatching, the surrounding
theca and granulosa cells from the follicular bed abandoned by the newly ovulated egg inter-
act to produce a corpus luteum, which retains sucient steroidogenic properties to produce
progesterone at the concentration required to regulate the endometrium, till the implantation
of a fertilized egg. If pregnancy does not occur, since the end of the luteal phase, gonadotropic
changes are prepared to allow the development of a follicular recruitment phase.
Being such a complex process, dependent on so many variables and exposed to so many
actions, reactions and interferences, the sequences of the menstrual cycle are remarkably pre-
dictable within not very wide ranges of variability. In general, the duration standards of each
cycle, 25–35 days, coincide with the ovulation presumption criteria accepted for women with
ovulatory anomalies such as in the polycystic ovarian syndrome. The detailed understand-
ing of the mechanisms allow to improve the eciency in the clinical management when it
Figure 20. The variability in perimenopause depends on the lag phase, a delayed recruitment process. Adapted from
Hale et al. [35].
Menstrual Cycle24
is intended to give assistance to obtain a pregnancy, as well as to avoid it when the goal is
contraception, or to correct bleeding anomalies that may result from ovulatory disorders with
luteal insuciency. There are still many aspects to investigate.
Conict of interest
The authors declare no conict of interest in relation to this publication.
Author details
Barriga-Pooley Patricio1* and Brantes-Glavic Sergio2
*Address all correspondence to: pbarriga@uft.cl
1 Obstetrics and Gynaecology Department, School of Medicine, Finis Terrae and San
Sebastian Universities, Santiago, Chile
2 Depto Ginecología y Obstericia, Universidad de Chile, Santiago, Chile
References
[1] Reed BG, Carr BR. The normal menstrual cycle and the control of ovulation. In: De Groot
LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, et al., editors.
Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000 (ver 2018 Aug 5.)
[2] Welt CK, Pagan YL, Smith PC, Rado KB, Hall JE. Control of follicle-stimulating hormone
by estradiol and the inhibins: Critical role of estradiol at the hypothalamus during the
luteal-follicular transition. The Journal of Clinical Endocrinology and Metabolism. 2003
Apr;88(4):1766-1771. DOI: 10.1210/jc.2002-021516
[3] Mihm M, Gangooly S, Muukrishna S. The normal menstrual cycle in women. Animal
Reproduction Science. 2011;124(3-4):229-236. DOI: 10.1016/j.anireprosci.2010.08.030
[4] Hodgen GD. The dominant ovarian follicle. Fertility and Sterility. 1982;38:281-300
[5] Macklon NS, Fauser BC. Aspects of ovarian follicle development throughout life.
Hormone Research. 1999;52(4):161-170. DOI: 10.1159/000023456
[6] Richards JS, Ren YA, Candelaria N, Adams JE, Rajkovic A. Ovarian follicular theca cell
recruitment, dierentiation, and impact on fertility: 2017 update. Endocrine Reviews.
Feb 1 2018;39(1):1-20. DOI: 10.1210/er.2017-00164
[7] Baird DT, Fraser IS. Blood production and ovarian secretion rates of esuadiol-17β and
estrone in women throughout the menstrual cycle. The Journal of Clinical Endocrinology
and Metabolism. 1974;38:1009-1017
Normal Menstrual Cycle 25
[8] Doshi SB, Agarwal A. The role of oxidative stress in menopause. Journal of Midlife
Health. 2013;4(3):140-146. DOI: 10.4103/0976-7800.118990
[9] Groome NP, Illingworth PJ, O'Brien M, Pai R, Rodger FE, Mather JP, et al. Measurement
of dimeric inhibin B throughout the human menstrual cycle. The Journal of Clinical
Endocrinology and Metabolism. 1996;81(4):1401-1405. DOI: 10.1210/jcem.81.4.8636341
[10] Welt CK, Martin KA, Taylor AE, Lambert-Messerlian GM, Crowley WF Jr, Smith JA,
et al. Frequency modulation of follicle-stimulating hormone (FSH) during the luteal-
follicular transition: Evidence for FSH control of inhibin B in normal women. The
Journal of Clinical Endocrinology and Metabolism 1997;82(8):2645-2652. DOI: 10.1210/
jcem.82.8.4138
[11] Small CM, Manatunga AK, Klein M, Feigelson HS, Dominguez CE, McChesney R, et al.
Menstrual cycle characteristics: Associations with fertility and spontaneous abortion.
Epidemiology. 2006 Jan;17(1):52-60
[12] Wilcox AJ, Dunson D, Baird DD. The timing of the "fertile window" in the menstrual
cycle: Day specic estimates from a prospective study. BMJ. 2000;321(7271):1259-1262.
DOI: 10.1136/bmj.321.7271.1259
[13] Wise LA, Mikkelsen EM, Rothman KJ, Riis AH, Sørensen HT, Huybrechts KF, et al. A
prospective cohort study of menstrual characteristics and time to pregnancy. American
Journal of Epidemiology. 2011;174(6):701-709. DOI: 10.1093/aje/kwr130
[14] La Marca A, Broekmans FJ, Volpe A, Fauser BC, Macklon NS, ESHRE Special Interest
Group for Reproductive Endocrinology–AMH Round Table. Anti-Mullerian hormone
(AMH): What do we still need to know? Human Reproduction. 2009 Sep;24(9):2264-2275.
DOI: 10.1093/humrep/dep210
[15] Broekmans FJ, Visser JA, Laven JS, Broer SL, Themmen AP, Fauser BC. Anti-Müllerian
hormone and ovarian dysfunction. Trends in Endocrinology and Metabolism. 2008
Nov;19(9):340-347. DOI: 10.1016/j.tem.2008.08.002
[16] Sollenberger MJ, Carlsen EC, Johnson ML, Veldhuis JD, Evans WS. Specic physi-
ological regulation of luteinizing hormone secretory events throughout the human men-
strual cycle: New insights into the pulsatile mode of gonadotropin release. Journal of
Neuroendocrinology. 1990;2(6):845-852. DOI: 10.1111/j.1365-2826.1990.tb00650.x
[17] Ho JD, Quigley ME, Yen SCC. Hormonal dynamics at midcycle: A re-evaluation. The
Journal of Clinical Endocrinology and Metabolism. 1983;57:792
[18] Irianni F, Hodgen GD. Mechanism of ovulation. Endocrinology and Metabolism Clinics
of North America. 1992;21(1):19-38. DOI: 10.1016/S0889-8529(18)30230-5
[19] Jesam C, Salvatierra AM, Schwar JL, Croxao HB. Suppression of follicular rupture
with meloxicam, a cyclooxygenase-2 inhibitor: Potential for emergency contraception.
Human Reproduction. 2010;25(2):368-373. DOI: 10.1093/humrep/dep392
[20] Duy DM. Novel contraceptive targets to inhibit ovulation: The prostaglandin E2 path-
way. Human Reproduction Update. 2015;21(5):652-670. DOI: 10.1093/humupd/dmv026
Menstrual Cycle26
[21] Russell DL, Robker RL. Molecular mechanisms of ovulation: Co-ordination through
the cumulus complex. Human Reproduction Update. 2007;13(3):289-312. DOI: 10.1093/
humupd/dml062
[22] Richards JS, Russell DL, Robker RL, Dajee M, Alliston TN. Molecular mechanisms of
ovulation and luteinization. Molecular and Cellular Endocrinology. 1998;145(1-2):47-54.
DOI: 10.1016/S0303-7207(98)00168-3
[23] Devoto L, Henríquez S, Kohen P, Strauss JF 3rd. The signicance of estradiol metabo-
lites in human corpus luteum physiology. Steroids. 2017;123:50-54. DOI: 10.1016/j.
steroids.2017.05.002
[24] Stocco C, Telleria C, Gibori G. The molecular control of corpus luteum formation, func-
tion, and regression. Endocrine Reviews. 2007;28(1):117-149. DOI: 10.1210/er.2006-0022
[25] Niswender GD. Molecular control of luteal secretion of progesterone. Reproduction.
2002;123(3):333-339
[26] Niswender GD, Juengel JL, Silva PJ, Rollyson MK, McIntush EW. Mechanisms control-
ling the function and life span of the corpus luteum. Physiological Reviews. 2000;80(1):
1-29. DOI: 10.1152/physrev.2000.80.1.1
[27] Christenson LK, Devoto L. Cholesterol transport and steroidogenesis by the corpus
luteum. Reproductive Biology and Endocrinology. 2003;1:90. DOI: 10.1186/1477-7827-1-90
[28] Henriet P, Cornet PB, Lemoine P, Galant C, Singer CF, Courtoy PJ, et al. Circulating ovar-
ian steroids and endometrial matrix metalloproteinases (MMPs). Annals of the New York
Academy of Sciences. 2002;955:119-138. DOI: 10.1111/j.1749-6632.2002.tb02773.x
[29] Munro MG, Critchley HO, Broder MS, Fraser IS, FIGO Working Group on Menstrual
Disorders. FIGO classication system (PALM-COEIN) for causes of abnormal uterine
bleeding in nongravid women of reproductive age. International Journal of Gynaeco-
logy and Obstetrics. 2011;113(1):3-13. DOI: 10.1016/j.ijgo.2010.11.011
[30] Hutchens EG, Ramsey KA, Howard LC, Abshire MY, Patrie JT, McCartney CR. Proge-
sterone has rapid positive feedback actions on LH release but fails to reduce LH pulse
frequency within 12 h in estradiol-pretreated women. Physiological Reports. 2016;4(16).
DOI: 10.14814/phy2.12891
[31] Kim SH, Burt Solorzano CM, McCartney CR. Progesterone administration does not
acutely alter LH pulse secretion in the mid-follicular phase in women. Physiological
Reports. 2018;6(8):e13680. DOI: 10.14814/phy2.13680
[32] Skorupskaite K, George JT, Anderson RA. The kisspeptin-GnRH pathway in human
reproductive health and disease. Human Reproduction Update. 2014;20(4):485-500.
DOI: 10.1093/humupd/dmu009
[33] Lehman MN, Coolen LM, Goodman RL. Minireview: Kisspeptin/neurokinin B/dynor-
phin (KNDy) cells of the arcuate nucleus: A central node in the control of gonadotro-
pin-releasing hormone secretion. Endocrinology. 2010;151(8):3479-3489. DOI: 10.1210/
en.2010-0022
Normal Menstrual Cycle 27
[34] Bilezikjian LM, Blount AL, Leal AM, Donaldson CJ, Fischer WH, Vale WW. Autocrine/
paracrine regulation of pituitary function by activin, inhibin and follistatin. Molecular
and Cellular Endocrinology. 2004 Oct 15;225(1-2):29-36. DOI: 10.1016/j.mce.2004.02.010
[35] Hale GE, Zhao X, Hughes CL, Burger HG, Robertson DM, Fraser IS. Endocrine features
of menstrual cycles in middle and late reproductive age and the menopausal transition
classied according to the staging of reproductive aging workshop (STRAW) staging
system. The Journal of Clinical Endocrinology and Metabolism. 2007;92(8):3060-3067
Menstrual Cycle28
... When fertilization does not occur, the layer prepared in the endometrium is shed, and menstruation occurs. 2 The execution of this process takes place by the hormones secreted from the hypothalamus and pituitary. Estrogen and progesterone hormones are secreted from the ovaries, which are under the control of gonadotropic hormones secreted from the anterior lobe of the pituitary. ...
... If fertilization has not occurred, estrogen and progesterone secretion decreases as a result of the effect of hormones on each other, causing the corpus luteum to degenerate and a new menstruation begins. 2 As a result of varying hormonal activities, the menstrual cycle has physical and psychological effects, such as pain, restlessness, irritability, depression, headache, nausea, dizziness, and imbalance, which vary from person to person. Especially 4-10 days before menstruation, estrogen, progesterone, and aldosterone levels rise and dizziness or imbalance can be seen due to these changes. ...
... The reason for this outcome is thought to be the increase in estrogen, progesterone, and aldosterone hormones in the premenstrual period, which coincides with the luteal phase. 2 The increase in these hormones causes the body to retain water and salt, causing a change in the homeostasis of ear fluids and affecting inner ear functions. 19 It is also thought that estrogen and progesterone directly affect the visual-vestibular interaction areas in the central system. ...
Article
Full-text available
Background: The aim of this study is to compare the possible functional involvement of the vestibulo-ocular reflex in the follicular and luteal phases. Methods: The research was carried out at a university located in eastern Turkey. The study included 37 healthy female volunteering students aged 18-25 years. The functional head impulse test was applied twice in the follicular phase and in the luteal phase, and the results in both phases were compared. Results: In the functional head impulse test, statistically significant differences were obtained between the follicular phase and the luteal phase at the stimulus to the lateral semicircular canal direction total and 6000°/s2 acceleration percentage of correct answers values, the posterior semicircular canal direction stimulations at 3000°/s2 and 5000°/s2 acceleration percentage of correct answers values, and the anterior semicircular canal direction stimulations at 5000°/s2 acceleration percentage of correct answers values. Conclusion: In the luteal phase, which corresponds to the period before menstruation, the vestibulo-ocular reflex is functionally negatively affected.
... The menstrual cycle is a regular and natural process that occurs within the female reproductive system (Schmalenberger et al., 2021). The reproductive cycle starts with menarche, the initial occurrence of menstruation in adolescence, and ends with menopause, a stage that facilitates fertilisation and potential pregnancy (Patricio & Sergio, 2019;Vogazianou, 2019). The duration of healthy menstrual cycles can range from 21 to 37 days, with cycles < 21 days being identified as polymenorrhea and cycles > 37 days as oligomenorrhea (De Sanctis et al., 2014). ...
Article
Full-text available
COVID-19 vaccinations have been associated with irregularities in the menstrual cycle and symptoms occurring pre and post-menstruation, affecting women’s reproductive health. This study aimed to demonstrate the impact of COVID-19 vaccines on women’s reproductive health by examining the association between COVID-19 vaccines and disturbed menstrual cycles. This cross-sectional survey-based study was conducted among adult females at King Saud University, Saudi Arabia, from April 2022 to August 2022. A total of 380 participants were selected through a stratified random sampling technique. Ethical approval was obtained from the Deanship of Scientific Research at King Saud University. The data were analysed using descriptive statistics and appropriate statistical tests. The results revealed that 53.9% of the participants experienced disturbances in the menstrual cycle after receiving the COVID-19 vaccination. Adult females aged 18-25 showed the highest rate of disorders. Menstrual disruptions were substantially correlated with marital status (p = 0.05), with a significant association between the number of COVID-19 vaccine doses and the occurrence of menstrual disturbances (p = 0.001). The administration of the vaccination during menstruation was linked to a notable occurrence of menstrual disturbances, although the p-value showed no statistical significance. A significant correlation was examined (p < 0.05) between pre-existing menstrual problems and the occurrence of disorders after receiving the COVID-19 vaccine (p < 0.05). The study emphasised the importance of tailored healthcare treatments for women following COVID-19 vaccination and the need for regular evaluation of reproductive health outcomes post-COVID-19 vaccination.
... If the egg is not fertilized, the corpus luteum degrades, causing a decrease in progesterone and estrogen levels during the late luteal phase. Meanwhile, the cycle prepares to restart, and the uterine lining is shed, initiating menstruation once again [55][56][57]. During the menstrual cycle, the metabolic rate during sleep exhibits cyclical changes, with the highest point occurring during the late luteal phase. ...
Article
Full-text available
The main objective of this study was to determine the differences in energy expenditure (EE) according to sex during and after two different squat training protocols in a group of healthy young adults. Twenty-nine Sports Sciences students volunteered to participate in this study. They attended the laboratory on four different days and completed four sessions: two sessions with 3 sets of 12 repetitions at 75% of their one-repetition maximum (RM) and two sessions with 3 sets of 30 repetitions at 50% of their 1RM. Energy expenditure was evaluated using an indirect calorimeter. Males consistently demonstrated higher EE in all sessions and intensities. The linear regression model identified a significant association between sex, BMI, and total EE across all sessions and intensities. In conclusion, males exhibited higher EE in both protocols (50% and 75% of 1RM) throughout all sessions. Furthermore, sex and BMI were found to influence EE in healthy young adults. Therefore, coaches should consider sex when assessing EE, as the metabolic response differs between males and females.
Article
Full-text available
Some folklore scholars regard African oral literature merely as a social pastime, a belief which other scholars have proved wrong. Northern Sotho folksongs, like other folklore genres, are not merely there to pass time, they also give messages to the singers and listeners. The main aim of this article is to reveal the two selected folksongs’ messages and to demonstrate that there is no folksong that is without a message. To achieve this, two Northern Sotho folksongs were purposefully selected because of their popularity. The study followed a qualititative research method, where pensioners, both men and women, were selected. What inspired this selection criterion was their wisdom and knowledge of folksongs. Though folksongs are meant to entertain, they do give meaning and value to the lives of the various people concerned. Each and every folksong brings about at least one important fact in life, overtly or covertly.
Chapter
Full-text available
In this survey, we review the current state of the art in mathematical modeling of the menstrual cycle. We compare and contrast different modeling choices and the benefits and limitations of various models. We investigate the sensitivity of these models to variations in parameter values, highlighting that these models display particular sensitivity to the growth rate of the reserve pool of follicular stimulating hormone. We also describe the incorporation of time delays in the model equations and discuss the ways in which these delays reflect the biological system and impact the dynamics. We explore the qualitative effects that introducing exogenous hormones into these models plays on inducing a contraceptive state. Through our comparative study of these models, we are able to highlight important areas of future work in the mathematical modeling of hormonal contraception and the menstrual cycle.
Article
Full-text available
Perdarahan uterus abnormal (PUA) merupakan kelainan di bidang ginekologi yang paling sering dialami oleh perempuan usia produktif yang ditandai dengan adanya perubahan pada siklus menstruasi baik dari interval atau panjang siklus, durasi maupun jumlah perdarahan. Dampak perdarahan uterus abnormal pada usia produktif diseluruh dunia cukup banyak dengan prevalensi sekitar 3-30%. Federation of Gynecology and Obstetrics (FIGO) mengklasifikasikan PUA menurut etiologinya menjadi struktural dan nonstruktural menggunakan PALM-COEIN: Polip, Adenomiosis, Leiomioma, Malignansi Dan Hiperplasia, Coagulopathy, Disfungsi Ovarium, Endometrial, Iatrogenik, dan Not Yet Classified. Klasifikasi PALM-COEIN dapat ditegakkan apabila terdapat riwayat pasien yang lengkap dikombinasikan dengan tes pencitraan yang tepat, analisis histopatologis ataupun pemeriksaan laboratorium untuk memastikan pendekatan diagnostik dan pengobatan yang akurat. Pada dasarnya tujuan penatalaksanaan PUA adalah memperbaiki keadaan umum, menghentikan perdarahan, dan mengembalikan fungsi hormon reproduksi. Menghentikan perdarahan dapat dilakukan dengan medikamentosa, dilatasi dan kuretase, maupun tindakan operatif.
Article
Menstrual döngü kadınlarda aylık olarak tekrar eden ve üremeyi sağlayan fizyolojik bir süreçtir. Menstrual döngü sırasında hormonal dalgalanmalar nedeniyle psikolojik değişiklikler meydana gelebilir. Premenstrüel sendrom (PMS) olarak tanımlanan bu psikolojik değişiklikler kadınların %20-40'ını etkiler. Adet döneminde beynin hipotalamus kısmındaki açlık ve tokluk merkezlerini etkilenmektedir. İştahın arttığı ve besin tercihinde değişikliklerin olduğu bildirilmektedir. Çikolata ve tatlılar gibi basit şekerler içeren, yağ ve tuz içeriği yüksek besinlerin tüketiminin arttığı tespit edilmiştir. Bu, artan enerji alımına ve diyet önerilerinin üzerinde basit şeker ve yağ alımına yol açar. Batı tarzı bir diyet benimseyen kadınlarda PMS'nin şiddetlendiği bildirilmiştir. Kompleks karbonhidratlar, yeterli protein, azaltılmış doymuş yağ, düşük kolesterol, basit şeker ve tuz içeren sağlıklı bir diyet modeli ile PMS şiddetinin azaltılabileceği düşünülmektedir.
Article
Full-text available
A better understanding of interindividual differences and the development of targeted therapies is one of the major challenges of modern medicine. The sex of a person plays a crucial role in this regard. This systematic review aimed to summarise and analyse available evidence on the mutual interactions between non-invasive brain stimulation and sex/polypeptide hormones. The PubMed database was searched from its inception to 31 March 2023, for (i) studies that investigated the impact of sex and/or polypeptide hormones on the effects induced by non-invasive brain stimulation, or (ii) studies that investigated non-invasive brain stimulation in the modulation of sex and/or polypeptide hormones. Eighteen studies (319 healthy and 96 disabled participants) were included. Most studies focused on female sex hormone levels during the menstrual cycle. The later follicular phase is associated with a weak between hemispheric and intracortical inhibition, strong intracortical facilitation, and high stimulation-induced neural and behavioural changes. The opposite effects are observed during the luteal phase. In addition, the participant’s sex, presence and/or absence of real ovulation and increase in oestradiol level by chorionic gonadotropin injection influence the stimulation-induced neurophysiological and behavioural effects. In Parkinson’s disease and consciousness disorders, the repetitive application of non-invasive brain stimulation increases oestradiol and dehydroepiandrosterone levels and reduces disability. To date, male hormones have not been sufficiently included in these studies. Here, we show that the sex and/or polypeptide hormones and non-invasive brain stimulation methods are in reciprocal interactions. This may be used to create a more effective and individualised approach for healthy individuals and individuals with disabilities.
Article
Full-text available
It remains unclear how rapidly progesterone suppresses luteinizing hormone (LH) pulse frequency in women. Previous studies suggested that progesterone markedly increases LH pulse amplitude but does not slow LH pulse frequency within 10 h in estradiol‐pretreated women studied during the late follicular phase. However, this experimental paradigm may be a model of preovulatory physiology, and progesterone may have different effects at other times of the cycle. We studied regularly cycling, nonobese women without hyperandrogenism to assess the acute effect of progesterone during the midfollicular phase and in the absence of estradiol pretreatment. The study involved two admissions in separate cycles (cycle days 5–9). For each admission, either oral micronized progesterone (100 mg) or placebo was administered at 0900 h in a randomized, double‐blind fashion. Frequent blood sampling was performed between 0900 and 1900 h to define 10‐h LH pulsatility. Treatment crossover (placebo exchanged for progesterone and vice versa) occurred in a subsequent cycle. After an interim futility analysis, the study was halted after 7 women completed study. Mean progesterone concentrations after placebo and progesterone administration were 0.5 ± 0.1 (mean ± SD) and 6.7 ± 1.6 ng/mL, respectively. Compared to placebo, progesterone was not associated with a significant difference in 10‐h LH pulse frequency (0.79 ± 0.35 vs. 0.77 ± 0.28 pulses/h, P = 1.0) or amplitude (3.6 ± 2.8 vs. 4.3 ± 2.8 IU/L, P = 0.30). This study suggests that LH pulse frequency is not rapidly influenced by progesterone administration during the midfollicular phase. The rapidity with which progesterone suppresses LH (GnRH) pulse frequency in women is unclear. This study, which was performed in women in the midfollicular phase, adds to available data suggesting that progesterone does not suppress LH (GnRH) pulse frequency within 10 h.
Article
Full-text available
In women, progesterone suppresses luteinizing hormone (LH) (gonadotropin-releasing hormone) pulse frequency, but how rapidly this occurs is unknown. In estradiol-pretreated women in the late follicular phase, progesterone administration at 1800 did not slow sleep-associated LH pulse frequency. However, mechanisms controlling LH pulse frequency may differ according to sleep status; and we thus hypothesized that progesterone acutely suppresses waking LH pulse frequency. This was a randomized, double-blind, crossover study of LH secretory responses to progesterone versus placebo administered at 0600. We studied 12 normal women in the late follicular phase (cycle days 7–11), pretreated with 3 days of transdermal estradiol (0.2 mg/day). Subjects underwent a 24-h blood sampling protocol (starting at 2000) and received either 100 mg oral micronized progesterone or placebo at 0600. In a subsequent menstrual cycle, subjects underwent an identical protocol except that oral progesterone was exchanged for placebo or vice versa. Changes in 10-h LH pulse frequency were similar between progesterone and placebo. However, mean LH, LH pulse amplitude, and mean follicle-stimulating hormone exhibited significantly greater increases with progesterone. Compared to our previous study (progesterone administered at 1800), progesterone administration at 0600 was associated with a similar increase in mean LH, but a less pronounced increase in LH pulse amplitude. We conclude that, in estradiol-pretreated women in the late follicular phase, a single dose of progesterone does not suppress waking LH pulse frequency within 12 h, but it acutely amplifies mean LH and LH pulse amplitude – an effect that may be influenced by sleep status and/or time of day.
Article
Full-text available
This review will discuss the concept of reproductive aging, which includes the definition of menopause, its symptoms, and predisposing conditions. It will elaborate upon the contributory factors implicated in the pathogenesis of menopause, focusing most prominently on oxidative stress. Specifically, this paper will explain how oxidative stress, in the form of free radicals and antioxidant deficiencies, has been directly linked to the decline of estrogen during reproductive aging. Additionally, this paper will elaborate upon the treatment options aimed at mitigating the menopausal symptoms and hormonal deficiencies that can lead to various disease processes. Treatment options such as hormonal therapy, antioxidant supplementation, and lifestyle modification have been explored for their effectiveness in treating and preventing the symptoms and sequelae of menopause. The majority of information in this review was obtained through PubMed and the National Library of Medicine. While most references in this paper are original research articles, a limited number of references are comprehensive reviews on the topic.
Article
The major goal of this review is to summarize recent exciting findings that have been published within the past 10 years that, to our knowledge, have not been presented in detail in previous reviews and that may impact altered follicular development in polycystic ovarian syndrome (PCOS) and premature ovarian failure (POF) in women. Specifically, we will cover 1) mouse models that have led to discovery of the derivation of two precursor populations of theca cells in the embryonic gonad, 2) the key roles of the oocyte-derived factor GDF9 on the hedgehog (HH) signaling pathway and theca cell functions and 3) the impact of the HH pathway on both the specification of theca endocrine cells and theca fibroblast and smooth muscle cells in developing follicles. We will also discuss 1) other signaling pathways that impact the differentiation of theca cells, not only LH but also INSL3, BMPs, the circadian clock genes, androgens and estrogens and 2) theca associated vascular, immune and fibroblast cells, as well as the cytokines and matrix factors that play key roles in follicle growth. Lastly, we will integrate what is known about theca cells from mouse models, human derived theca cell lines from PCOS and non-PCOS patients and microarray analyses of human and bovine theca to understand what pathways and factors contribute to follicle growth as well as to the abnormal function of theca
Article
The human corpus luteum (CL) is a temporary endocrine gland derived from the ovulated follicle. Its formation and limited lifespan is critical for steroid hormone production required to support menstrual cyclicity, endometrial receptivity for successful implantation, and the maintenance of early pregnancy. Endocrine and paracrine-autocrine molecular mechanisms associated with progesterone production throughout the luteal phase are critical for the development, maintenance, regression, and rescue by hCG which sustains CL function into early pregnancy. However, the signaling systems driving the regression of the primate corpus luteum in non-conception cycles are not well understood. Recently, there has been interest in the functional roles of estradiol metabolites (EMs), mostly in estrogen-producing tissues. The human CL produces a number of EMs, and it has been postulated that the EMs acting via paracrine-autocrine pathways affect angiogenesis or LH-mediated events. The present review describes advances in understanding the role of EMs in the functional lifespan and regression of the human CL in non-conception cycles.
Article
Cholesterol provided by low- or high-density lipoprotein is the precursor for biosynthesis of progesterone. Once inside the cell, cholesterol can be used for steroidogenesis or esterified with long-chain fatty acids and stored as cholesterol esters in lipid droplets. When it is needed for steroidogenesis, free cholesterol is transported to the mitochondrion via a mechanism that involves cytoskeletal elements and sterol carrier proteins. Cytochrome P450 cholesterol side chain cleavage enzyme complex converts the cholesterol to pregnenolone, which is then converted to progesterone by 3beta-hydroxysteroid dehydrogenase/Delta(5),Delta(4) isomerase in the smooth endoplasmic reticulum. Transport of cholesterol from the cytoplasm to the inner mitochondrial membrane is both the rate-limiting step in progesterone biosynthesis and the step most acutely influenced by second messengers. Steroidogenic acute regulatory protein (StAR) and peripheral-type benzodiazepine receptors (PBR) are involved in this transport. StAR may bind cholesterol in the cytosol and transport it to the mitochondrial membrane where PBR is involved in transport from the outer to the inner mitochondrial membrane. Phosphorylation of StAR by protein kinase A (PKA) stimulates cholesterol transport, whereas phosphorylation by PKC may inhibit this process. Endozepine, the natural ligand for PBR, also appears to be involved in regulation of the rate of cholesterol transport to the inner mitochondrial membrane and to play a role in the stimulatory effects of PKA on steroidogenesis. Increased concentrations of endozepine were detected in large luteal cells, and may explain the increased progesterone secretion from this type of cell. Fluorescence energy transfer procedures indicate that StAR associates with PBR in mitochondrial membranes. A model is presented for the proposed interactions of StAR, PBR and endozepine in the transport of cholesterol from the outer to the inner mitochondrial membrane.
Article
Background: Prostaglandin E2 (PGE2) is an essential intrafollicular regulator of ovulation. In contrast with the one-gene, one-protein concept for synthesis of peptide signaling molecules, production and metabolism of bioactive PGE2 requires controlled expression of many proteins, correct subcellular localization of enzymes, coordinated PGE2 synthesis and metabolism, and prostaglandin transport in and out of cells to facilitate PGE2 action and degradation. Elevated intrafollicular PGE2 is required for successful ovulation, so disruption of PGE2 synthesis, metabolism or transport may yield effective contraceptive strategies. Methods: This review summarizes case reports and studies on ovulation inhibition in women and macaques treated with cyclooxygenase inhibitors published from 1987 to 2014. These findings are discussed in the context of studies describing levels of mRNA, protein, and activity of prostaglandin synthesis and metabolic enzymes as well as prostaglandin transporters in ovarian cells. Results: The ovulatory surge of LH regulates the expression of each component of the PGE2 synthesis-metabolism-transport pathway within the ovulatory follicle. Data from primary ovarian cells and cancer cell lines suggest that enzymes and transporters can cooperate to optimize bioactive PGE2 levels. Elevated intrafollicular PGE2 mediates key ovulatory events including cumulus expansion, follicle rupture and oocyte release. Inhibitors of the prostaglandin-endoperoxide synthase 2 (PTGS2) enzyme (also known as cyclooxygenase-2 or COX2) reduce ovulation rates in women. Studies in macaques show that PTGS2 inhibitors can reduce the rates of cumulus expansion, oocyte release, follicle rupture, oocyte nuclear maturation and fertilization. A PTGS2 inhibitor reduced pregnancy rates in breeding macaques when administered to simulate emergency contraception. However, PTGS2 inhibition did not prevent pregnancy in monkeys when administered to simulate monthly contraceptive use. Conclusion: PTGS2 inhibitors alone may be suitable for use as emergency contraceptives. However, drugs of this class are unlikely to be effective as monthly contraceptives. Inhibitors of additional PGE2 synthesis enzymes or modulation of PGE2 metabolism or transport also hold potential for reducing follicular PGE2 and preventing ovulation. Approaches which target multiple components of the PGE2 synthesis-metabolism-transport pathway may be required to effectively block ovulation and lead to the development of novel contraceptive options for women. Therapies which target PGE2 may also impact disorders of the uterus and could also have benefits for women's health in addition to contraception.
Article
Objectives: To provide specific estimates of the likely occurrence of the six fertile days (the “fertile window”) during the menstrual cycle. Design: Prospective cohort study. Participants: 221 healthy women who were planning a pregnancy. Main outcome measures: The timing of ovulation in 696 menstrual cycles, estimated using urinary metabolites of oestrogen and progesterone. Results: The fertile window occurred during a broad range of days in the menstrual cycle. On every day between days 6 and 21, women had at minimum a 10% probability of being in their fertile window. Women cannot predict a sporadic late ovulation; 4-6% of women whose cycles had not yet resumed were potentially fertile in the fifth week of their cycle. Conclusions: In only about 30% of women is the fertile window entirely within the days of the menstrual cycle identified by clinical guidelines—that is, between days 10 and 17. Most women reach their fertile window earlier and others much later. Women should be advised that the timing of their fertile window can be highly unpredictable, even if their cycles are usually regular.